Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapyCORNELISSEN, Marion; BACK, Nicole Kt; BURGER, David M et al.Antiviral therapy (London). 2011, Vol 16, Num 6, pp 931-935, issn 1359-6535, 5 p.Article

A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophyBLÜMER, Regje M. E; VAN DER VALK, Marc; ACKERMANS, Mariette et al.American journal of physiology. Endocrinology and metabolism. 2009, Vol 60, Num 5, pp 1097-1104, issn 0193-1849, 8 p.Article

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsVAN LEEUWEN, Remko; KATLAMA, Christine; MORONI, Mauro et al.AIDS (London). 2003, Vol 17, Num 7, pp 987-999, issn 0269-9370, 13 p.Article

Impact of nevirapine on lipid metabolismCLOTET, Bonaventura; VAN DER VALK, Marc; NEGREDO, Eugenia et al.Journal of acquired immune deficiency syndromes (1999). 2003, Vol 34, pp S79-S84, issn 1525-4135, SUP1Conference Paper

Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. CommentaryVAN DER VALK, Marc; BISSCHOP, Peter H; ROMIJN, Johannes A et al.AIDS (London). 2001, Vol 15, Num 16, pp 2093-2100, issn 0269-9370, 10 p.Article

Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissueDEN BOER, Marion A. M; BERBEE, Jimmy F. P; REISS, Peter et al.Arteriosclerosis, thrombosis, and vascular biology. 2006, Vol 26, Num 1, pp 124-129, issn 1079-5642, 6 p.Article

Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in hiv-1-infected patients randomly allocated to zidovudine- or stavudine-based therapyVAN DER VALK, Marc; CASULA, Miriam; DE RONDE, Anthony et al.Antiviral therapy (London). 2004, Vol 9, Num 3, pp 385-393, issn 1359-6535, 9 p.Article

Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGE_hIV Cohort StudySCHOUTEN, Judith; WIT, Ferdinand W; STOLTE, Ineke G et al.Clinical infectious diseases. 2014, Vol 59, Num 12, pp 1787-1797, issn 1058-4838, 11 p.Article

Sympathetic nervous system function in HIV-associated adipose redistribution syndromeVAN GURP, Petra J; TACK, Cees J; VAN DER VALK, Marc et al.AIDS (London). 2006, Vol 20, Num 5, pp 773-775, issn 0269-9370, 3 p.Article

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic ConsiderationsDE KANTER, Clara T. M. M; DRENTH, Joost P. H; ARENDS, Joop E et al.Clinical pharmacokinetics. 2014, Vol 53, Num 5, pp 409-427, issn 0312-5963, 19 p.Article

Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patientsVAN DER VALK, Marc; ALLICK, Gideon; REISS, Peter et al.The Journal of clinical endocrinology and metabolism. 2004, Vol 89, Num 7, pp 3554-3560, issn 0021-972X, 7 p.Article

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profileVAN DER VALK, Marc; KASTELEIN, John J. P; MOLHUIZEN, Henri O. F et al.AIDS (London). 2001, Vol 15, Num 18, pp 2407-2414, issn 0269-9370Article